170 related articles for article (PubMed ID: 37408680)
1. Survival in Metastatic Renal Cell Carcinoma Treated With Immunotherapy and Stereotactic Radiation Therapy or Immunotherapy Alone: A National Cancer Database Analysis.
Piening A; Al-Hammadi N; Dombrowski J; Hamilton Z; Teague RM; Swaminath A; Shahi J
Adv Radiat Oncol; 2023; 8(5):101238. PubMed ID: 37408680
[TBL] [Abstract][Full Text] [Related]
2. Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic body radiation therapy or systemic therapy alone.
Piening A; Swaminath A; Dombrowski J; Teague RM; Al-Hammadi N; Shahi J
Front Oncol; 2023; 13():1290691. PubMed ID: 38090505
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma.
Kroeze SGC; Fritz C; Schaule J; Siva S; Kahl KH; Sundahl N; Blanck O; Kaul D; Adebahr S; Verhoeff JJC; Skazikis G; Roeder F; Geier M; Eckert F; Guckenberger M
BJU Int; 2021 Jun; 127(6):703-711. PubMed ID: 33113260
[TBL] [Abstract][Full Text] [Related]
4. Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy.
Meagher MF; Minervini A; Mir MC; Cerrato C; Rebez G; Autorino R; Hampton L; Campi R; Kriegmair M; Linares E; Hevia V; Musquera M; D'Anna M; Roussel E; Albersen M; Pavan N; Claps F; Antonelli A; Marchioni M; Paksoy N; Erdem S; Derweesh IH
Eur Urol Open Sci; 2024 May; 63():71-80. PubMed ID: 38572300
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System.
Nguyen EK; Lalani AKA; Ghosh S; Basappa NS; Kapoor A; Hansen AR; Kollmannsberger C; Heng D; Wood LA; Castonguay V; Soulières D; Winquist E; Canil C; Graham J; Bjarnason GA; Breau RH; Pouliot F; Swaminath A
Adv Radiat Oncol; 2022; 7(4):100899. PubMed ID: 35814860
[TBL] [Abstract][Full Text] [Related]
6. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis.
Foster CC; Sher DJ; Rusthoven CG; Verma V; Spiotto MT; Weichselbaum RR; Koshy M
Radiat Oncol; 2019 Jan; 14(1):18. PubMed ID: 30691492
[TBL] [Abstract][Full Text] [Related]
7. Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy.
Sheng IY; Gupta S; Reddy CA; Angelini D; Funchain P; Sussman TA; Sleiman J; Ornstein MC; McCrae K; Khorana AA
Target Oncol; 2021 Nov; 16(6):813-821. PubMed ID: 34741719
[TBL] [Abstract][Full Text] [Related]
8. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
9. Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort.
Hoeh B; Schmucker P; Klümper N; Hahn O; Zeuschner P; Banek S; Karakiewicz PI; Ellinger J; Heinzelbecker J; Hölzel M; Strauß A; Zengerling F; Mattigk A; Kalogirou C
Urol Int; 2022; 106(11):1150-1157. PubMed ID: 35158357
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibition in patients treated with stereotactic radiation for brain metastases.
Kowalski ES; Remick JS; Sun K; Alexander GS; Khairnar R; Morse E; Cherng HR; Berg LJ; Poirier Y; Lamichhane N; Becker S; Chen S; Molitoris JK; Kwok Y; Regine WF; Mishra MV
Radiat Oncol; 2020 Oct; 15(1):245. PubMed ID: 33109224
[TBL] [Abstract][Full Text] [Related]
11. Single fraction stereotactic radiosurgery and fractionated stereotactic radiotherapy provide equal prognosis with overall survival in patients with brain metastases at diagnosis without surgery at primary site.
Ostdiek-Wille GP; Amin S; Wang S; Zhang C; Lin C
PeerJ; 2023; 11():e15357. PubMed ID: 37223122
[TBL] [Abstract][Full Text] [Related]
12. Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy.
Riveros C; Ranganathan S; Xu J; Chang C; Kaushik D; Morgan M; Miles BJ; Muhammad T; Anis M; Aghazadeh M; Zhang J; Efstathiou E; Klaassen Z; Brooks MA; Rini B; Wallis CJD; Satkunasivam R
Urol Oncol; 2023 Mar; 41(3):150.e1-150.e9. PubMed ID: 36610815
[TBL] [Abstract][Full Text] [Related]
13. Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma.
Navani V; Ernst M; Wells JC; Yuasa T; Takemura K; Donskov F; Basappa NS; Schmidt A; Pal SK; Meza L; Wood LA; Ernst DS; Szabados B; Powles T; McKay RR; Weickhardt A; Suarez C; Kapoor A; Lee JL; Choueiri TK; Heng DYC
JAMA Netw Open; 2022 Jun; 5(6):e2216379. PubMed ID: 35687336
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy plus stereotactic body radiation therapy or whole-brain radiation therapy in brain metastases.
Amin S; Baine M; Lin C
Immunotherapy; 2023 Feb; 15(3):163-174. PubMed ID: 36748364
[No Abstract] [Full Text] [Related]
15. Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016.
Sussman TA; Knackstedt R; Wei W; Funchain P; Gastman BR
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35998982
[TBL] [Abstract][Full Text] [Related]
16. Metastatic renal cell carcinoma to the pancreas and other sites-a multicenter retrospective study.
Duarte C; Hu J; Beuselinck B; Panian J; Weise N; Dizman N; Collier KA; Rathi N; Li H; Elias R; Martinez-Chanza N; Rose TL; Harshman LC; Gopalakrishnan D; Vaishampayan U; Zakharia Y; Narayan V; Carneiro BA; Mega A; Singla N; Meguid C; George S; Brugarolas J; Agarwal N; Mortazavi A; Pal S; McKay RR; Lam ET
EClinicalMedicine; 2023 Jun; 60():102018. PubMed ID: 37304495
[TBL] [Abstract][Full Text] [Related]
17. Survival Benefit of Stereotactic Radiotherapy in the Complex Management of Metastatic Melanoma.
Kelemen G; Együd Z; Dobi Á; Varga L; Kószó R; Borzási E; Paczona V; Végváry Z; Borzák F; Fodor E; Ócsai H; Baltás E; Oláh J; Hideghéty K
Anticancer Res; 2024 Jan; 44(1):205-212. PubMed ID: 38159978
[TBL] [Abstract][Full Text] [Related]
18. Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b).
Stellato M; Santini D; Verzoni E; De Giorgi U; Pantano F; Casadei C; Fornarini G; Maruzzo M; Sbrana A; Di Lorenzo G; Soraru M; Naglieri E; Buti S; De Vivo R; Napolitano A; Vignani F; Mucciarini C; Grillone F; Roviello G; Di Napoli M; Procopio G
Front Oncol; 2021; 11():682449. PubMed ID: 34168997
[TBL] [Abstract][Full Text] [Related]
19. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
Savard MF; Wells JC; Graham J; Dudani S; Steinharter JA; McGregor BA; Donskov F; Bjarnason GA; Vaishampayan UN; Hansen AR; Iafolla MAJ; Zanotti G; Huynh L; Chang R; Duh MS; Heng DYC
Oncologist; 2020 May; 25(5):422-430. PubMed ID: 31971318
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]